PCIA
ALNY icon

Prime Capital Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Prime Capital Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,716
Closed -$328K – 1015
2023
Q4 		$328K Buy
+1,716
New +$292K 0.01% 710

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prime Capital Investment Advisors's ALNY Position: Q1 2024 in Review

Prime Capital Investment Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 1,716 shares — an estimated $328K sold.

Prime Capital Investment Advisors first reported a position in ALNY in Q4 2023 and held it in 1 quarter. The position peaked at $328K in Q4 2023. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Prime Capital Investment Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 1,716 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $328K.
  • Prime Capital Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Prime Capital Investment Advisors's Alnylam Pharmaceuticals position peaked at $328K in Q4 2023.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2024, filed 15 May 2024.